Study Evaluating PSI-697 in Patients With Scleritis

Status Terminated

Clinical Trial Summary

To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind

Related Conditions & MeSH terms

Scleritis

Clinical Trial Details

NCT number	NCT00367692
Study type	Interventional
Source	Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status	Terminated
Phase	Phase 1
Start date	September 2006
Completion date	April 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03660618` - LSFG-SKIN, Laser Speckle Flowgraphy	N/A
Enrolling by invitation	`NCT01613963` - Causes of Visual Loss in Retinal Disease	N/A
Completed	`NCT03753893` - Ocular Manifestations in Rheumatic Diseases
Completed	`NCT01835132` - Gevokizumab for Active Scleritis	Phase 1/Phase 2
Completed	`NCT02764697` - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients	Phase 4
Completed	`NCT01517074` - Sirolimus Injections for Autoimmune Scleritis	Phase 1/Phase 2
Completed	`NCT00415506` - Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation	Phase 1/Phase 2
Recruiting	`NCT03465111` - A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis	Phase 2
Completed	`NCT00075075` - Infliximab to Treat Non-Infectious Scleritis	Phase 1
Recruiting	`NCT05200715` - AutoInflammatory Disease Alliance Registry (AIDA)
Terminated	`NCT00539370` - Human Samples and Data Repository
Active, not recruiting	`NCT03580343` - Tofacitinib for Inflammatory Eye Disease	Phase 2